Journal Information
Vol. 59. Issue 7.
Pages 439-440 (July 2023)
Share
Share
Download PDF
More article options
Vol. 59. Issue 7.
Pages 439-440 (July 2023)
Case Report
Full text access
Mepolizumab and Eosinophilic Pleural Effusion in Patient With Eosinophilic Granulomatosis With Polyangiitis
Visits
2760
María del Carmen Lorenzo Martíneza,
Corresponding author
carmenlorenzomtz@gmail.com

Corresponding author.
, Oscar Clavería Garcíaa, María Dolores Herrero Mendozab, José Javier Jareño Estebana
a Pneumology Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain
b Internal Medicine Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

We present a 71-year-old woman with a long-standing history of severe eosinophilic asthma (por controlled with ACT scale of 15) and nasal polyposis, with suspected poor adherence to treatment at follow-up.

The patient was admitted to our hospital with clinical manifestations of cough and whitish expectoration. During physical examination, partial respiratory failure and semiology of asthmatic exacerbation with hypophonesis in lower pulmonary lobes were found. X-ray, and then chest CT, were requested showing consolidation in the upper lobes and bilateral pleural effusion (Fig. 1). Laboratory data showed no biochemistry alterations, NT-proBNP 262pg/ml, CRP 2.62mg/dl and leukocytosis 15,180/mcL (eosinophils 3.990/mcL, 27%). The ANAs, MPO-ANCA, PR3-ANCA, microbiology and serology were all negative (virus, bacteria and parasites).

Fig. 1.

Chest CT. Left image: bilateral pleural effusion predominantly on the left side with secondary passive atelectasis. Right image: bilateral infiltrates.

(0.15MB).

In view of patient's poor respiratory progress, we performed a diagnostic thoracentesis, obtaining a yellowish non-hematic exudate with the following characteristics: pH 7.20, protein 6g/dl, glucose 214mg/dl, LDH 203U/L and leukocytes 6780/mcL (50% eosinophils). Cytology and microbiology were negative. It was decided to carry out a nasal turbinate biopsy, that showed eosinophilic infiltration of the corium. Polyneuropathy was ruled out.

EGPA was diagnosed classifying it as a nonsevere with a “Five Factor Score” (FFS) of zero. Treatment was started with prednisone 50mg and mepolizumab 100mg per day, progressively escalating to mepolizumab 300mg per day. After 6 months of full-dose treatment, the patient presented an excellent clinical and radiological improvement with complete resolution of eosinophilic pleural effussion (EPE).

According to the American College of Rheumatology (1990),1 more than 4 of the next 6 criteria are necessary for EGPA diagnosis: asthma, peripheral eosinophilia (>10%), neuropathy, sinusitis, extravascular eosinophilia and evanescent pulmonary infiltrates. Eosinophilic pleural effusion is a rare complication,2 with an incidence of 29% in patients with EGPA. Its characteristics have not been well described, having been defined by more than 10% eosinophil count, low pH and low glucose. Differential diagnoses of EPE include rheumatoid arthritis, bacterial pneumonia, tuberculosis, parasitosis, pharmacological, neoplasms, hematological disorders and, less frequently, certain vasculitis.

There is no standard therapy for the management of EGPA.3 Currently, the cornerstone of treatment consist of systemic glucocorticosteroids, with a relapse rate of 35%. In this context, immunosuppressive agents are used for maintaining remission. In spite of that, high dose of glucocorticoids and immunosuppressants may have long-term adverse effects. Recently, clinical benefits of mepolizumab have been demonstrated in patients with EGPA. MIRRA trial4 included patients with refractory EGPA treated with prednisone, demonstrating remission in 87% of patients treated with mepolizumab versus 53% in the placebo group. An European Observacional Study compared mepolizumab 300mg versus 100mg dose, showing both doses are associated with effective control of systemic EGPA manifestations.5

Therefore, mepolizumab is now a good therapeutic option for EGPA. It should be considered as a steroid-sparing drug used for maintenance of remission and control of non-organ-threatening flares, but not as a treatment for active organ-threatening disease.

Conflict of interests

The authors state that they have no conflict of interests.

References
[1]
A.T. Masi, G.G. Hunder, J.T. Lie, B.A. Michel, D.A. Bloch, W.P. Arend, et al.
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).
Arthritis Rheum, 33 (1990), pp. 1094-1100
[2]
K. Tanizawa, Y. Kaji, E. Tanaka, T. Inoue, M. Sakuramoto, M. Minakuchi, et al.
Massive eosinophilic pleural effusion preceding vasculitic symptoms in Churg-Strauss syndrome.
Intern Med, 49 (2010), pp. 841-845
[3]
S.A. Chung, C.A. Langford, M. Maz, A. Abril, M. Gorelik, G. Guyatt, et al.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheumatol, 73 (2021), pp. 1366-1383
[4]
M.E. Wechsler, P. Akuthota, D. Jayne, P. Khoury, A. Klion, C.A. Langford, et al.
Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis.
N Engl J Med, 376 (2017), pp. 1921-1932
[5]
A. Bettiol, M.L. Urban, L. Dagna, V. Cottin, F. Franceschini, S. Del Giacco, et al.
Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study.
Arthritis Rheumatol, 74 (2022), pp. 295-306
Copyright © 2023. SEPAR
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?